ID   ZYXY-M2
AC   CVCL_B6YM
DR   CCRID; 4201PAT-CCTCC01830
DR   Wikidata; Q112041951
RX   DOI=10.1182/blood-2021-152639;
RX   Patent=CN113549597B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC 202145.
CC   Population: Chinese.
CC   Doubling time: 48-72 hours (DOI=10.1182/blood-2021-152639).
CC   Karyotypic information: 47,XY,+12 [1]; 48,XY,+12,+9 [9] (DOI=10.1182/blood-2021-152639).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Patent=CN113549597B
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D12S391: 17,19
ST   D13S317: 8,9
ST   D16S539: 11,13
ST   D18S51: 14,16
ST   D19S433: 14
ST   D1S1656: 13,17
ST   D21S11: 29
ST   D2S1338: 23,25
ST   D3S1358: 16,17
ST   D5S818: 10,14
ST   D6S1043: 11,14
ST   D7S820: 10,12
ST   D8S1179: 14,15
ST   FGA: 21,22
ST   Penta D: 10,11
ST   Penta E: 14,15
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C2862; Primary myelofibrosis
DI   ORDO; Orphanet_824; Primary myelofibrosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 29-06-23; Version: 5
//
RX   DOI=10.1182/blood-2021-152639;
RA   Zhou Y.-L., Li F.-L., Jin J.;
RT   "Establishment and characterization of a human primary myelofibrosis
RT   cell line.";
RL   Blood 138 Suppl. 1:4594-4594(2021).
//
RX   Patent=CN113549597B;
RA   Jin J., Li F.-L., Zhou Y.-L., Yu W.-J., Wang J.-H., Huang X.,
RA   Wang Y.-G.;
RT   "Human primary myelofibrosis cell line and application thereof.";
RL   Patent number CN113549597A, 25-Mar-2022.
//